BCRX - BioCryst Pharmaceuticals - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart

BCRX is currently covered by 9 analysts with an average price target of $21.64. This is a potential upside of $14.42 (199.72%) from yesterday's end of day stock price of $7.22.

Our record on BCRX covers 19 analysts since 2008; 9 cover it today. Of the 187 price targets those analysts set on BCRX, 96 were reached (51%). The highest performance score on BCRX belongs to Liisa Bayko of Evercore: 4.33, with 9 of 12 targets met in 683 days on average. The latest calls: Laura Chico of Wedbush cut the target to $17 from $20 with a Buy rating on 5 Nov 2026; Jessica Fye of JPMorgan raised the target to $13 from $12 with a Hold rating on 30 Sep 2026; Brian Abrahams of RBC cut the target to $11 from $14 with a Buy rating on 10 Sep 2026. Figures as of 18 Nov 2026.

BioCryst Pharmaceuticals's activity chart (see below) currently has 241 price targets and 204 ratings on display. The stock rating distribution of BCRX is 90% BUY and 10% HOLD.

Stock Analyst Price Targets - Review

Analysts' price targets on this stock were met 48.81% of the time, taking 284.85 days on average.

Highest price target for BCRX is $32, Lowest price target is $11, average price target is $21.64.

Most recent stock forecast was given by LAURA CHICO from WEDBUSH on 05-Nov-2026. First documented stock forecast 31-Jul-2013.

Currently out of the existing stock ratings of BCRX, 18 are a BUY (90%), 2 are a HOLD (10%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 30-Jun-2025

$17

$9.78 (135.46%)

$20

16 days ago
(05-Nov-2026)

0/6 (0%)

$9.37 (122.80%)

Hold Since 13-Jul-2026

$13

$5.78 (80.06%)

$12

1 months 22 days ago
(30-Sep-2026)

6/9 (66.67%)

$4.67 (56.06%)

234

Buy Since 25-Sep-2023

$11

$3.78 (52.35%)

$14

2 months 11 days ago
(10-Sep-2026)

28/35 (80%)

$2.71 (32.69%)

353

Buy Since 20-Apr-2023

$16

$8.78 (121.61%)

$16

2 months 13 days ago
(08-Sep-2026)

5/20 (25%)

$6.93 (76.41%)

334

Buy Since 03-Nov-2023

$17

$9.78 (135.46%)

$15

4 months 22 days ago
(30-Jun-2026)

9/12 (75%)

$7 (70.00%)

344

Show more analysts

Please expand the browser size to see the chart

What is BCRX (BioCryst Pharmaceuticals) average time for price targets to be met?

On average it took 285 days for the stock forecasts to be reached, with an average price target met ratio of 48.81%.

Which analyst most recently updated their price target on BCRX (BioCryst Pharmaceuticals)?

Laura Chico

Which analyst has the most public recommendations on BCRX (BioCryst Pharmaceuticals)?

Laura Chico works at WEDBUSH and has 44 price targets and 24 ratings on BCRX

Which analyst is the currently most bullish on BCRX (BioCryst Pharmaceuticals)?

Andrew Fein with the highest potential upside of $24.78

Which analyst is the currently most reserved on BCRX (BioCryst Pharmaceuticals)?

Gavin Clark-Gartner with the lowest potential downside of -$1.94
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

To continue looking at analysts data please register to the advanced membership

What is AnaChart?